Bladder squamous cell carcinoma
MONDO:0002760A squamous cell carcinoma of the bladder arising from metaplastic epithelium. It represents less than 10% of bladder carcinomas. The exception is the Middle East along the Nile Valley, where it represents the most common form of carcinoma because of the endemic nature of schistosomiasis. Bladder squamous cell carcinoma is often associated with long-standing chronic inflammation of the bladder and usually has a poor prognosis. The diagnosis of squamous cell carcinoma of the bladder should be reserved for those tumors that are predominantly keratin forming.
Also known as: bladder epidermoid carcinoma, bladder squamous cell cancer, bladder squamous cell carcinoma, epidermoid carcinoma of bladder, epidermoid carcinoma of the bladder, epidermoid carcinoma of the urinary bladder, epidermoid carcinoma of urinary bladder, squamous cell carcinoma of bladder
2766 clinical trials for this condition and its sub-types, 5 tagged with Bladder squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Bladder squamous cell carcinoma
-
Bladder verrucous carcinoma 0 trials
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for rare cancers: drug combo shows promise in early trial
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with rare cancers of the bladder, urinary tract, or testicles. The study aims to see if these drugs can shrink tumors or slow disease progression. About 68 adults will receiv…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a targeted antibody-drug combo tackle rare bladder cancers?
Disease control Recruiting nowThis phase II trial is testing whether combining enfortumab vedotin—a drug that delivers a cancer-killing agent directly to tumor cells—with the immunotherapy pembrolizumab can shrink tumors in people with locally advanced or metastatic bladder cancer of variant histology. These …
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC